PSNL — Personalis, Inc.

Summary of Personalis Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $14.5 million for Q3 2025, down 44% year-over-year from $25.7 million. The decline was attributed to reduced revenue from Natera, the VA MVP, and biopharma customers.
• Biopharma Revenue: $13.2 million, a 16% decrease from $15.7 million in the prior year, primarily due to the conclusion of Moderna's Phase III melanoma trial.
• Clinical Tests: 4,388 tests delivered, representing a 26% sequential growth and 364% year-over-year growth.
• Gross Margin: 13.2%, down from 34% year-over-year, impacted by lower revenue volume and increased clinical test costs.
• Net Loss: $21.7 million, improved from a loss of $39.1 million in the same quarter last year.
• Cash Position: $150.5 million in cash and short-term investments, with operational cash usage of $23.4 million in Q3.

2. Strategic Updates and Business Highlights

• Win-in-MRD Strategy: Continued execution with significant growth in clinical test volumes and an expanding base of over 700 physicians ordering NeXT Personal tests.
• Reimbursement Efforts: Submitted three dossiers for coverage, targeting two decisions by the end of 2025. Recent clinical evidence supports the efficacy of NeXT Personal in detecting cancer recurrence earlier than standard imaging.
• Partnerships: Collaboration with Tempus has exceeded expectations, achieving primary volume targets early. Two major prospective clinical trials were signed this quarter, indicating strong demand for MRD testing.

3. Forward Guidance and Outlook

• Revised Revenue Guidance: Full-year revenue expected to be between $68 million and $73 million, down from a previous range of $70 million to $80 million.
• Clinical Revenue: Expected to contribute $1.5 million to $2 million, reduced from $3 million to $6 million due to pending reimbursement approvals.
• Gross Margin: Projected to be between 22% and 24%, reflecting ongoing investments in clinical test volume.

4. Challenges and Points of Concern

• Biopharma Volatility: Continued variability in biopharma project timing and logistical delays, particularly with customs affecting sample receipt, which may impact Q4 revenue.
• Declining Revenue from Legacy Contracts: Significant revenue declines from Natera and the VA MVP as those contracts wind down.
• Competitive Pressures: The entry of new competitors in the MRD testing space raises concerns about sustaining growth rates and market share.

5. Notable Q&A Insights

• Customer Adoption: Both large pharma customers have come online, contributing significantly to MRD revenue, which is expected to grow threefold year-over-year.
• Logistical Delays: Challenges with customs have caused sample delays, leading to a wider revenue guidance range for Q4.
• Market Penetration: The focus is on deepening relationships with existing accounts rather than solely acquiring new customers, which is expected to enhance revenue per physician.
• Feedback from Tempus: Positive feedback from physicians regarding the value proposition of NeXT Personal, emphasizing the importance of ultrasensitivity in MRD testing.

Overall, Personalis is making significant strides in clinical adoption and reimbursement efforts, despite facing challenges related to revenue volatility and competitive pressures. The company remains optimistic about future growth driven by its strategic initiatives and partnerships.